Table 2.
Antimicrobial susceptibility percentage (susceptible, intermediate, and resistant) of the 29 P. aeruginosa isolates obtained from the ear canals of dogs.
| Antimicrobial agent | Disk concentration (μg) | Breakpoints (mm; ≤S/I/R<)a | Number of susceptible isolates (%) | Number of Intermediate isolates (%) | Number of resistant isolates (%) |
|---|---|---|---|---|---|
| Ceftazidime (CAZ) | 30 | 18/15–17/14 | 27 (93.1) | 1 (3.4) | 1 (3.4) |
| Cefpodoxime (CPDX) | 10 | 21/18–20/17 | 0 (0.0) | 0 (0.0) | 29 (100) |
| Cefovecin (CFV) | 10 | 21/18–20/17 | 0 (0.0) | 0 (0.0) | 29 (100) |
| Cefepime (CFPM) | 30 | 18/15–17/14 | 27 (93.1) | 2 (6.9) | 0 (0.0) |
| Aztreonam (AZT) | 30 | 22/16–21/15 | 10 (34.5) | 3 (10.3) | 16 (55.2) |
| Piperacillin-Tazobactam (PIP/TAZ) | 110 | 21/15–20/14 | 25 (86.2) | 4 (13.8) | 0 (0.0) |
| Gentamicin (GM) | 10 | 15/13–14/12 | 26 (89.7) | 0 (0.0) | 3 (10.3) |
| Tobramycin (TOB) | 10 | 15/13–14/12 | 26 (89.7) | 1 (3.4) | 2 (6.9) |
| Fradiomycin (FRM) | 10 | 15/13–14/12 | 14 (48.3) | 10 (34.5) | 5 (17.2) |
| Amikacin (AMK) | 30 | 17/15–16/14 | 4 (13.8) | 9 (31) | 16 (55.2) |
| Ciprofloxacin (CIP) | 5 | 21/16–20/15 | 2 (6.9) | 2 (6.9) | 25 (86.2) |
| Ofloxacin (OFLX) | 5 | 16/13–15/12 | 21 (72.5) | 1 (3.4) | 7 (24.1) |
| Lomefloxacin (LFLX) | 10 | 22/19–21/18 | 13 (44.8) | 7 (24.1) | 9 (31) |
| Levofloxacin (LVLX) | 5 | 17/14–16/13 | 4 (13.9) | 6 (20.6) | 19 (65.5) |
| Orbifloxacin (OBFX) | 10 | 23/17–22/16 | 4 (13.9) | 9 (31) | 16 (55.2) |
| Enrofloxacin (ERFX) | 10 | 23/17–22/16 | 3 (10.3) | 13 (44.8) | 13 (44.8) |
| Florfenicol (FF) | 30 | 16/11–15/10 | 0 (0.0) | 0 (0.0) | 29 (100) |
aS, susceptible; I, intermediate; R, resistant.